Fluicell publishes 2023 Half-year report
Today, August 2023, Fluicell publishes the financial report for the period January 1 to June 30, 2023. The…
Microenvironment modeling with high precision bioprinitng
The cell microenvironment plays a key role in many biological processes. Replicating the cell microenvironment and the complex…
05
Jul
2023
New study reveals potential treatment for premenstrual dysphoric disorder
Premenstrual dysphoric disorder (PMDD) is a mood disorder affecting up to 8% of all menstruating women that greatly…
28
Jun
2023
Fluicell CEO Newsletter 02, 2023
Changing research at the core has been a driving force for us at Fluicell from the start. Through…
14
Jun
2023
Fluicell Capital Markets Day
Updtae 2023-05-23 All the talks from the Capital Markets Day are now available here: https://fluicell.com/capital-markets-day-2023/. You can also…
22
May
2023
“Fluicell is advancing in the right direction” interview with CEO Victoire Viannay
Our plan is to continue to advance in all our three business areas: research solutions, human in vitro…
19
May
2023
Closing the loop on type 1 diabetes – therapeutic development whitepaper
Fluicell’s type 1 diabetes development program is aimed at creating patient-tailored artificial pancreatic islets capable of enabling glycemic…
16
May
2023
Fluicell publishes 2023 Q1 interim report
Today, May 12 2023, Fluicell publishes the Q1 interim report for the period January to March, 2023. The…
12
May
2023
90 students experience bioprinting at Fluicell
We at Fluicell are passionate about research and science and always want to take the opportunity to inspire…
08
May
2023